The apelinergic system: a perspective on challenges and opportunities in cardiovascular and metabolic disorders.
The apelinergic pathway has been generating increasing interest in the past few years for its potential as a therapeutic target in several conditions associated with the cardiovascular and metabolic systems. Indeed, preclinical and, more recently, clinical evidence both point to this G protein-coupled receptor as a target of interest in the treatment of not only cardiovascular disorders such as heart failure, pulmonary arterial hypertension, atherosclerosis, or septic shock, but also of additional conditions such as water retention/hyponatremic disorders, type 2 diabetes, and preeclampsia. While it is a peculiar system with its two classes of endogenous ligand, the apelins and Elabela, its intricacies are a matter of continuing investigation to finely pinpoint its potential and how it enables crosstalk between the vasculature and organ systems of interest. In this perspective article, we first review the current knowledge on the role of the apelinergic pathway in the above systems, as well as the associated therapeutic indications and existing pharmacological tools. We also offer a perspective on the challenges and potential ahead to advance the apelinergic system as a target for therapeutic intervention in several key areas.
['Marsault|Eric|E|0000-0002-5305-8762', 'Llorens-Cortes|Catherine|C|0000-0002-7667-0401', 'Iturrioz|Xavier|X|0000-0001-7143-8323', 'Chun|Hyung J|HJ|0000-0003-3508-2678', 'Lesur|Olivier|O|', 'Oudit|Gavin Y|GY|0000-0002-9154-9028', 'Auger-Messier|Mannix|M|0000-0001-8600-5440']
D000818:Animals D000073861:Apelin D002318:Cardiovascular Diseases D006801:Humans D008659:Metabolic Diseases D059748:Proteolysis D015398:Signal Transduction
heart failure pulmonary arterial hypertension hypertension septic shock water retention/hyponatremic disorders type 2 diabetes preeclampsia apelin Apela/Toddler/Elabela apelin receptor/APLNR/APJ cardiovascular protection